About Us

WAVE Life Sciences to Present at the Deutsche Bank 41st Annual Health Care Conference

WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicines company focused on developing stereopure nucleic acid therapies for patients with rare diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will present at the Deutsche Bank 41st Annual Health Care Conference at 3:30 PM EDT on Wednesday, May 4, 2016 in Boston, Mass.

About WAVE Life Sciences
At WAVE Life Sciences, we are driven by an unwavering passion and commitment to deliver on our mission of confronting challenging diseases by developing transformational therapies and empowering patients to live the lives they choose. We are utilizing our innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare and other serious genetically defined diseases. Given the versatility of our chemistry platform, WAVE’s deep, diverse pipeline spans multiple modalities including antisense, exon-skipping, and single-stranded RNAi. For more information, please visit www.wavelifesciences.com and follow us on Twitter at @WAVELifeSci and LinkedIn.

Contacts:

Investor Contact:
Westwicke Partners
Chris Brinzey, 339-970-2843
chris.brinzey@westwicke.com
or
Media Contact:
Feinstein Kean Healthcare
Liz Melone, 617-256-6622
liz.melone@fkhealth.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.